Galderma Group AG/ADR Business Summary

Galderma Group AG (GALDY) operates as a global pure-play dermatology leader, generating revenue through the research, development, and commercialization of specialized skin health products across three primary segments: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company’s business model is centered on a high-margin product sales strategy, leveraging flagship brands such as Restylane, Dysport, and Sculptra in the aesthetics market, Cetaphil in the consumer skincare space, and Nemluvio in the therapeutic sector. As of early 2026, Galderma has significantly expanded its therapeutic footprint, particularly in prurigo nodularis and atopic dermatitis, while maintaining a dominant position in the neuromodulator and filler categories. Its primary direct competitors include AbbVie (Allergan), Sanofi, and L’Oréal’s Dermatological Beauty division; Galderma distinguishes itself by maintaining a comprehensive, science-based portfolio that spans the entire spectrum of dermatology, positioning it as a premium, integrated alternative to diversified pharmaceutical and consumer goods conglomerates. Originally established in 1981 as a joint venture between Nestlé and L’Oréal, Galderma is currently led by CEO Flemming Ørnskov, M.D., MPH, the former CEO of Shire, who has overseen the company’s transition from a private entity to a public corporation following its 2024 SIX Swiss Exchange listing. The executive team includes Thomas J. Dittrich, who serves as Chief Financial Officer through the second quarter of 2026, with Luigi La Corte (formerly of Recordati and GSK) appointed to succeed him effective May 1, 2026. Other key leaders include Adrian Murphy (Head of Global Operations) and Emil Ivanov (Head of Strategy). The company’s Board of Directors is chaired by Thomas Ebeling, former CEO of Novartis Pharma and ProSiebenSat.1, and includes Vice-Chair Sherilyn McCoy, former CEO of Avon Products. While now a public entity, Galderma remains backed by a significant legacy investment from an EQT-led consortium, which orchestrated its 2019 carve-out from Nestlé Skin Health.